Advertisement

The 2020 SGO Annual Meeting Report

      When we thought of this theme for the 2020 Annual Meeting well over a year ago, we did not anticipate that the vision for the future would entail rapid evolution of how we interact, function, care for patients, and advance science as a Society. And while we were unable to have our Annual Meeting in person, we were given the opportunity to grow as Program Chairs and as a Program Committee to adapt to these new challenges encountered. This was a year that brought about a significant amount of new information from trials around the world with broad-ranging impact on the current and future practice of gynecologic oncology. In this Annual Meeting Report, we highlight the carefully manicured digital retooling of the science that was to be presented at the 2020 SGO Annual Meeting in Toronto. The science was carefully curated, and then broken down and newly formatted into eight themed, digestible webinar sessions, which included distillations for practical clinical applications of each session. Though necessary, it was not ideal to have to cancel our Annual Meeting. Our dutiful Program Committee remained engaged with the responsibility to deliver our data, reported here, to our Society in an organized, timely, and interactive manner.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013 May 2;497(7447):67–73. Erratum in: Nature. 2013 Aug 8;500(7461):242. PMID: 23636398.

      2. Oaknin A, Duska LR, Sullivan RJ, et al. Preliminary safety, efficacy, and pharmacokinetic/pharmacodynamic characterization from GARNET, a phase I/II clinical trial of the anti PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-H and MSS endometrial cancer. Presented at: 2019 SGO Annual Meeting; March 16–19, 2019; Honolulu, HI. Abstract 33.

      3. Fader AN, Roque DM, Siegel E, et al. Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. J Clin Oncol. 2018 Jul 10;36(20):2044-2051. PMID 29584549.

        • Gonzalez-Martin A.
        • Pothuri B.
        • Vergote I.
        • et al.
        Niraparib in patients with newly diagnosed advanced ovarian cancer.
        N. Engl. J. Med. 2019; 381: 2391-2402
      4. FDA label for niraparib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf Last Accessed April 30, 2020.

        • Ray-Coquard I.
        • Pautier P.
        • Pignata S.
        • et al.
        Olaparib plus bevacizumab as first-line maintenance in ovarian cancer.
        N. Engl. J. Med. 2019; 381: 2416-2428
        • Coleman R.L.
        • Fleming G.F.
        • Brady M.F.
        • et al.
        Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer.
        N. Engl. J. Med. 2019; 381: 2403-2415